CO2023009342A2 - Proteínas de unión condicionalmente biespecíficas - Google Patents

Proteínas de unión condicionalmente biespecíficas

Info

Publication number
CO2023009342A2
CO2023009342A2 CONC2023/0009342A CO2023009342A CO2023009342A2 CO 2023009342 A2 CO2023009342 A2 CO 2023009342A2 CO 2023009342 A CO2023009342 A CO 2023009342A CO 2023009342 A2 CO2023009342 A2 CO 2023009342A2
Authority
CO
Colombia
Prior art keywords
immune cells
tumor
conditionally
binding proteins
bispecific binding
Prior art date
Application number
CONC2023/0009342A
Other languages
English (en)
Inventor
Patricia A Culp
Tseng-Hui Timothy Chen
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2023009342A2 publication Critical patent/CO2023009342A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación, en algunos aspectos, proporciona construcciones de activación redirigida biespecífica condicional coestimuladora, o «COBRA coestim», que se administran en un formato de profármaco activo. Tras la exposición a las proteasas tumorales, las construcciones se escinden y se activan, de modo que pueden unirse tanto a los antígenos diana tumorales (TTA) como a las células inmunitarias (p. ej., uno o más tipos de células inmunitarias), para reclutar así células inmunitarias al tumor, lo que da como resultado un tratamiento.
CONC2023/0009342A 2020-12-14 2023-07-13 Proteínas de unión condicionalmente biespecíficas CO2023009342A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125267P 2020-12-14 2020-12-14
PCT/IB2021/000868 WO2022130013A1 (en) 2020-12-14 2021-12-14 Conditionally bispecific binding proteins

Publications (1)

Publication Number Publication Date
CO2023009342A2 true CO2023009342A2 (es) 2024-01-15

Family

ID=80222325

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009342A CO2023009342A2 (es) 2020-12-14 2023-07-13 Proteínas de unión condicionalmente biespecíficas

Country Status (10)

Country Link
EP (1) EP4259663A1 (es)
JP (1) JP2023552865A (es)
KR (1) KR20230131210A (es)
CN (1) CN116964090A (es)
AU (1) AU2021402183A1 (es)
BR (1) BR112023011782A2 (es)
CA (1) CA3201978A1 (es)
CO (1) CO2023009342A2 (es)
MX (1) MX2023006869A (es)
WO (1) WO2022130013A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342521A (zh) * 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
CN108653728B (zh) 2011-06-23 2022-11-18 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
KR102162413B1 (ko) 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
PE20212205A1 (es) 2017-09-08 2021-11-18 Maverick Therapeutics Inc Proteinas de union condicionalmente activadas restringidas
US20210290676A1 (en) * 2018-07-30 2021-09-23 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
WO2020181140A1 (en) * 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
CA3201978A1 (en) 2022-06-23
JP2023552865A (ja) 2023-12-19
CN116964090A (zh) 2023-10-27
MX2023006869A (es) 2023-08-14
AU2021402183A1 (en) 2023-07-06
BR112023011782A2 (pt) 2023-10-31
AU2021402183A9 (en) 2024-02-08
WO2022130013A1 (en) 2022-06-23
EP4259663A1 (en) 2023-10-18
KR20230131210A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
CO2020001113A2 (es) Muteínas de interleucina 21 y métodos de tratamiento
CO2023009342A2 (es) Proteínas de unión condicionalmente biespecíficas
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
CY1123035T1 (el) Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CO2023002164A2 (es) Proteínas de unión restringidas activadas de forma condicional
AR069981A1 (es) Los "anticuerpo modificado geneticamente que reconocen cd138".
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
DOP2015000050A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
AR086241A1 (es) Proteinas repetitivas de union a il4/il13 y usos
BRPI0817482B8 (pt) uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
CO2022000481A2 (es) Inhibidores de enzimas
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al